Cypress Bioscience, Inc. trades in the stock market as ticker CYPB. Business Summary & Profile For Cypress Bioscience, Inc..

Cypress Bioscience, Inc.

Cypress Bioscience, Inc. develops and commercializes pharmaceutical products and personalized medicine laboratory services to rheumatologists in the United States. The company is developing milnacipran, norepinephrine serotonin reuptake inhibitor for fibromyalgia syndrome. The milnacipran is a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine. It has collaboration/license agreements with Collegium Pharmaceutical, Inc.; Forest Laboratories, Inc.; and Pierre Fabre. The company was founded in 1981 and is based in San Diego, California.
No related news found for this Cypress Bioscience, Inc..

Write Comment Create Account

Quotes are delayed for NASDAQ, NYSE, OTC, OTCBB (Penny Stocks) and NYSE Amex when available. Quotes and other information supplied by independent providers and feeds. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Localnewsnor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing Localnews, you agree not to redistribute the information found therein.

Privacy Policy - WE KEEP YOUR PERSONAL DATA PRIVATE AND CONFIDENTIAL - Localnews is committed to protecting the privacy of all our visitors and subscribers. Your right to privacy is very important to us. When you choose to provide us with information about yourself, we recognize that you trust us to act in a responsible manner. SHARING OF INFORMATION - Localnews does not sell, rent, lease or share any user information that it has collected over this website.

@2012 www.localnewsnow.org - Contact Us / Privacy Policy